<?xml version="1.0" encoding="UTF-8"?>
<feed xmlns="http://www.w3.org/2005/Atom"  xmlns:media="http://search.yahoo.com/mrss/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:itunes="http://www.itunes.com/dtds/podcast-1.0.dtd" xmlns:geo="http://www.w3.org/2003/01/geo/wgs84_pos#" xmlns:georss="http://www.georss.org/georss" xmlns:photo="http://www.pheed.com/pheed/">
 <title>Daily CSR</title>
 <subtitle><![CDATA[Daily CSR delivers latest news and in-depth coverage about corporate social responsibility, ethics and sustainability]]></subtitle>
 <link rel="alternate" type="text/html" href="https://www.dailycsr.com" />
 <link rel="self" type="text/xml" href="https://www.dailycsr.com/xml/atom.xml" />
 <id>https://www.dailycsr.com/</id>
 <updated>2026-04-24T11:04:01+02:00</updated>
 <generator uri="http://www.wmaker.net">Webzine Maker</generator>
  <icon>https://www.dailycsr.com/favicon.ico</icon>
  <entry>
   <title>US Air Pollution Report: Nearly Half of Children Exposed to Unsafe Air</title>
   <updated>2026-04-22T12:17:00+02:00</updated>
   <id>https://www.dailycsr.com/US-Air-Pollution-Report-Nearly-Half-of-Children-Exposed-to-Unsafe-Air_a5728.html</id>
   <category term="Companies" />
   <photo:imgsrc>https://www.dailycsr.com/photo/art/imagette/96192789-67107511.jpg</photo:imgsrc>
   <published>2026-04-22T12:16:00+02:00</published>
   <author><name>Debashish Mukherjee</name></author>
   <content type="html">
    <![CDATA[
     <div style="position:relative; text-align : center; padding-bottom: 1em;">
      <img src="https://www.dailycsr.com/photo/art/default/96192789-67107511.jpg?v=1776853071" alt="US Air Pollution Report: Nearly Half of Children Exposed to Unsafe Air" title="US Air Pollution Report: Nearly Half of Children Exposed to Unsafe Air" />
     </div>
     <div>
      <div style="text-align: justify;">The American Lung Association has released the 27th edition of its annual “State of the Air” report, revealing that nearly half of children across the United States are exposed to unhealthy air pollution levels. Despite notable improvements in air quality over the past five decades, about 152 million people still live in regions with dangerous concentrations of ozone or particle pollution. Recent policy changes by the U.S. Environmental Protection Agency (EPA), which have weakened clean air protections, are expected to increase exposure to harmful pollutants—especially among children. <br />   <br />  The report evaluates air quality in counties based on levels of ground-level ozone (commonly known as smog) and both short-term and year-round particle pollution (often called soot), using data collected between 2022 and 2024. It also ranks counties and metro areas from cleanest to most polluted for each category. <br />   <br />  Findings show that 33.5 million children—around 46% of those under 18—live in areas that received failing grades for at least one type of air pollution. Over 7 million children (10%) reside in places that failed all three measures. <br />   <br />  Young people are particularly vulnerable to air pollution because their lungs are still developing, they inhale more air relative to their body size, and they spend more time outdoors. Exposure during childhood can lead to lasting health effects, including reduced lung development, increased asthma risk, respiratory illnesses, and even cognitive challenges later in life. More broadly, both ozone and particle pollution are linked to severe health outcomes such as premature death, asthma attacks, heart attacks, strokes, preterm births, and lung cancer. <br />   <br />  Harold Wimmer, President and CEO of the American Lung Association, emphasized that clean air requires ongoing effort. While the Clean Air Act has historically improved air quality, he warned that progress is being threatened by climate-related factors like extreme heat and wildfires, along with policy decisions that weaken protections. He called for stronger standards, noting that recent EPA actions have reduced enforcement and rolled back safeguards aimed at limiting pollution from power plants and vehicles. He stressed the importance of clean air for children’s health and community well-being. <br />   <br />  Overall, the report indicates that 44% of the U.S. population—about 152 million people—live in counties that failed at least one pollution measure, while 32.9 million people live in areas that failed all three. It also highlights disparities, showing that people of color are more than twice as likely as white individuals to live in areas with failing grades across all pollution metrics. Hispanic communities, in particular, are over three times as likely to face such conditions. <br />   <br />  The report also draws attention to the growing number of data centers as a potential contributor to air pollution. Although specific emissions data is not yet available, the increasing reliance on fossil fuel-powered data centers may add to local pollution levels. <br />   <br />  The Lung Association urges the public to advocate for stronger protections, emphasizing the EPA’s critical role in safeguarding health. It warns that recent policy shifts, including the removal of health-related considerations from economic analyses, could lead to underestimating the true impact of pollution on children and communities. <br />   <br />  Key findings on ozone pollution show that over 129 million people—about 38% of the population—live in counties with failing grades, an increase of nearly 4 million from the previous year. Factors such as extreme heat and wildfire smoke have contributed to worsening ozone levels, particularly across central states and regions stretching from California to Texas. <br />   <br />  Regarding particle pollution, 61.5 million people experienced harmful short-term spikes, while 75.9 million lived in areas with unhealthy year-round levels—making it one of the highest figures recorded in the report’s history. <br />   <br />  Finally, the report notes a decline in the number of cities with clean air. Only Bangor, Maine met the criteria for cleanest cities across all three pollution measures this year, compared to two cities last year and five in 2024, signaling an overall deterioration in air quality nationwide.</div>  
     </div>
     <br style="clear:both;"/>
    ]]>
   </content>
   <link rel="alternate" href="https://www.dailycsr.com/US-Air-Pollution-Report-Nearly-Half-of-Children-Exposed-to-Unsafe-Air_a5728.html" />
  </entry>
  <entry>
   <title>Viatris Global Health Initiatives: Advancing NCD Care, Mental Health, and Digital Therapeutics</title>
   <updated>2025-10-17T11:44:00+02:00</updated>
   <id>https://www.dailycsr.com/Viatris-Global-Health-Initiatives-Advancing-NCD-Care-Mental-Health-and-Digital-Therapeutics_a5204.html</id>
   <category term="Companies" />
   <photo:imgsrc>https://www.dailycsr.com/photo/art/imagette/91830855-64456625.jpg</photo:imgsrc>
   <published>2025-10-17T11:41:00+02:00</published>
   <author><name>Debashish Mukherjee</name></author>
   <content type="html">
    <![CDATA[
     <div style="position:relative; text-align : center; padding-bottom: 1em;">
      <img src="https://www.dailycsr.com/photo/art/default/91830855-64456625.jpg?v=1760694271" alt="Viatris Global Health Initiatives: Advancing NCD Care, Mental Health, and Digital Therapeutics" title="Viatris Global Health Initiatives: Advancing NCD Care, Mental Health, and Digital Therapeutics" />
     </div>
     <div>
      <div style="text-align: justify;">Noncommunicable diseases (NCDs) are the world’s leading cause of death, creating an immense strain on individuals, healthcare systems, and economies. Every year, around 18 million people die prematurely—before reaching 70—from NCDs such as cardiovascular diseases, cancers, chronic respiratory conditions, and diabetes. Most of these deaths occur in low- and lower-middle-income nations.¹ <br />   <br />  Viatris’ extensive portfolio—spanning both established and innovative medicines—targets many of these health challenges, including cardiovascular disease, diabetes, respiratory illnesses, dermatologic conditions, and eye disorders. In 2024, Viatris advanced access to essential treatments through several global initiatives:</div>    <ul>  	<li style="text-align: justify;">Global licensing collaboration: Viatris signed an exclusive licensing agreement with Lexicon Pharmaceuticals to distribute <em>sotagliflozin</em> outside the U.S. and Europe. This therapy, approved by the U.S. FDA, reduces cardiovascular death and hospitalizations in adults with heart failure or type 2 diabetes, chronic kidney disease, or other risk factors.</li>  	<li style="text-align: justify;">U.S. launch: The company introduced <em>RYZUMVI™</em> (phentolamine ophthalmic solution), the only FDA-approved eye drop available in the U.S. to reverse dilation caused by certain medications.</li>  	<li style="text-align: justify;">China: <em>Dymista</em> was launched to enhance symptom relief for patients with moderate to severe allergic rhinitis.</li>  	<li style="text-align: justify;">Europe: Viatris introduced <em>Rizmoic</em> (naldemedine tablets) in seven countries—an innovative treatment addressing opioid-induced constipation by targeting its underlying cause.</li>  	<li style="text-align: justify;">Canada: The release of <em>PrGlatiramer Acetate Injection 20 mg/mL</em>, a generic version of <em>Copaxone®</em>, provided a new treatment option for people living with relapsing-remitting multiple sclerosis (RRMS).</li>  	<li style="text-align: justify;">Australia: Several therapies, including <em>Relpax Migraine</em>, <em>Dymista Allergy</em>, and <em>Celebrex Relief</em>, became available over the counter, broadening access to acute treatment options.</li>  	<li style="text-align: justify;">Japan: The company launched <em>Cystadrops Ophthalmic Solution 0.38%</em> for cystinosis-related corneal deposits and <em>Sugammadex</em> IV injections to reverse muscle relaxation post-anesthesia.</li>  	<li style="text-align: justify;">Global approvals: <em>Elidel®</em> was approved for use in infants aged three months and older across the EU, China, and additional Asian markets—offering safer eczema treatment for young children.</li>  	<li style="text-align: justify;">India: <em>Neurontin NT</em> and <em>Neurontin M</em> expanded the range of pain management therapies.</li>  	<li style="text-align: justify;">Philippines: <em>Apixaban</em>, a branded generic anticoagulant for stroke prevention and clot treatment, was launched.</li>  	<li style="text-align: justify;">Brazil: Viatris introduced <em>Zeforus</em> (Relpax), the first eletriptan hydrobromide formulation for acute migraine relief.</li>  </ul>    <div style="text-align: justify;">“MS Canada estimates that approximately 90,000 Canadians live with multiple sclerosis—one of the highest prevalence rates globally. Because symptoms vary widely, access to a range of therapeutic options is essential,”&nbsp;Jeffrey L., Canada Country Manager, Viatris <br />  &nbsp; <br />  <strong>Combating Cardiovascular Disease</strong> <br />  Cardiovascular disease remains the foremost contributor to NCD-related deaths worldwide.² Viatris is tackling this global challenge through prevention, diagnosis, and treatment efforts, supported by an expansive portfolio and strategic collaborations. <br />   <br />  Key 2024 initiatives included:</div>    <ul>  	<li style="text-align: justify;">Developing four educational podcasts in Europe for healthcare professionals (HCPs) on diagnosing and managing thrombotic disorders, emphasizing anticoagulation monitoring, optimal treatment duration, and risk reduction in surgical settings.</li>  	<li style="text-align: justify;">Launching ViaHeart (La Via del Cuore) in Italy, an omnichannel awareness campaign encouraging heart-healthy lifestyles and medication adherence.</li>  	<li style="text-align: justify;">Hosting Egypt’s first Neuro Summit, addressing stroke management and its connections to hypertension, diabetes, and dyslipidemia.</li>  	<li style="text-align: justify;">Supporting the World Heart Federation’s Cholesterol Roadmap Project in Türkiye to promote dyslipidemia awareness and treatment.</li>  </ul>    <div style="text-align: justify;">The partnership with Lexicon Pharmaceuticals for <em>sotagliflozin</em> further strengthened Viatris’ cardiovascular portfolio, broadening access to patients globally through its extensive infrastructure. <br />  &nbsp; <br />  <strong>Addressing Hypertension</strong> <br />  High blood pressure is a critical cardiovascular risk factor that increases the likelihood of heart disease, stroke, and other complications. Viatris’ 2024 efforts focused on raising awareness, educating healthcare providers, and enhancing treatment access:</div>    <ul>  	<li style="text-align: justify;">Partnered with the Saudi Hypertension Management Society (SHMS) to train over 10,000 HCPs and support the “Everyday Count” campaign promoting hospital-based hypertension screening.</li>  	<li style="text-align: justify;">Collaborated with the Philippine Society of Hypertension and a local government unit to educate and screen 300 patients.</li>  	<li style="text-align: justify;">Contributed to the Chinese Hypertension Guideline (2024), supporting the development of the HOPE Asia Multidisciplinary Consensus on High-Quality Hypertension Management, expected to be released in 2025.</li>  	<li style="text-align: justify;">Organized educational meetings across Türkiye, engaging more than 250 HCPs through the Global Hypercare Project on blood pressure variability (BPV) control.</li>  	<li style="text-align: justify;">Worked with the Bulgarian Patients Forum to produce hypertension-focused health podcasts.</li>  	<li style="text-align: justify;">Led Project Challenge: Hypertension and Dyslipidemia in Italy as part of a global “train-the-trainer” initiative.</li>  	<li style="text-align: justify;">Developed a BPV advocacy plan across Asia, the Middle East, and Europe, reaching over 10,000 HCPs.</li>  </ul>    <div style="text-align: justify;">&nbsp; <br />  <strong>Promoting Mental Health</strong> <br />  Roughly one in eight people worldwide live with a mental health condition—most commonly anxiety or depression.³ Despite growing global awareness, barriers such as stigma, limited literacy, and inadequate services persist. Viatris continues to collaborate globally to improve mental health awareness, training, and access to care. <br />   <br />  <strong>Awareness Initiatives</strong></div>    <ul>  	<li style="text-align: justify;">Supported “Tear Away the Silence,” a UAE podcast series by <em>mentl</em>, reaching 5.5 million people.</li>  	<li style="text-align: justify;">Partnered with Türkiye’s Association of Psychiatric Sciences and Research (PiBAD) for the <em>Hayata Varım</em> campaign to challenge stigma.</li>  	<li style="text-align: justify;">Continued Brazil’s Yellow September Campaign, “Love Me, Love Myself,” alongside ABRATA.</li>  	<li style="text-align: justify;">Backed Mexico’s “Words Matter” project to guide responsible mental health reporting in media.</li>  </ul>    <div style="text-align: justify;"><strong>Education and Policy Collaboration</strong></div>    <ul>  	<li style="text-align: justify;">Supported the creation of evidence-based mental health care guidelines in Brazil, integrating training and continuous patient support in primary care.</li>  	<li style="text-align: justify;">Signed an MoU with Egypt’s Ministry of Health to co-fund the <em>Your Health is Happiness</em> program under the national <em>100 Million Health</em> initiative, aiming to screen 2 million people for mental health conditions and raise public awareness.</li>  </ul>    <div style="text-align: justify;"><strong>Research and Innovation</strong></div>    <ul>  	<li style="text-align: justify;">Filed for approval of <em>Effexor®</em> in Japan for generalized anxiety disorder, supported by Phase 3 study data demonstrating safety and efficacy.</li>  </ul>    <div style="text-align: justify;"><strong>Creative Engagement</strong> <br />  The Viatris Foundation in Spain hosted <em>La Mente sobre el Lienzo</em> (“Mind on Canvas”) at the Museo Nacional Centro de Arte Reina Sofía, exploring how art can foster empathy and dialogue about mental health. <br />   <br />  “Art can be a powerful medium for emotional expression, helping people living with mental health conditions feel seen, supported, and understood,” João M., President, Viatris Spain Foundation <br />  &nbsp; <br />  <strong>Expanding Access Through Digital Health</strong> <br />  Viatris is harnessing technology and digital therapeutics (DTx) to enhance patient care and access—particularly in underserved areas. DTx are evidence-based software interventions that help prevent, manage, or treat various conditions, often using AI and machine learning to personalize care. <br />   <br />  In Europe, Viatris co-authored <em>Adoption of Digital Therapeutics in Europe</em>, a study assessing regulatory, reimbursement, and implementation challenges. <br />   <br />  Additional digital initiatives included:</div>    <ul>  	<li style="text-align: justify;">WhatsApp Connect (WACR) in Malaysia, reaching nearly 2,000 HCPs with medical updates.</li>  	<li style="text-align: justify;">Bliss DTx in France, a virtual reality solution to manage pain and anxiety.</li>  	<li style="text-align: justify;">A three-year grant to Egypt’s Drug Authority supporting the DAWANA digital medication management tool.</li>  	<li style="text-align: justify;">Partnerships in China with Meituan Pharmacy, JD Health, and Alibaba Health Pharmacy to enhance out-of-hospital care access.</li>  	<li style="text-align: justify;">Participation in Gravitate Health, a transatlantic project developing digital tools like <em>G-Lens</em> for safe and informed medicine use.</li>  	<li style="text-align: justify;">The Score Diabetes App in Vietnam to help doctors visualize cardiovascular risk in diabetic patients.</li>  	<li style="text-align: justify;">A Diabetic Peripheral Neuropathy App pilot in Thailand to support early screening and intervention.</li>  </ul>    <div style="text-align: justify;">&nbsp; <br />  <strong>Encouraging Responsible Medicine Use</strong> <br />  Ensuring patients use medications safely and adhere to treatment plans is central to Viatris’ mission. The company provides digital tools—including websites, portals, and apps—to track symptoms, manage refills, and offer real-time insights for healthcare providers. <br />   <br />  Across Europe, Viatris also supports individual dose dispensing systems to minimize medication errors and improve adherence, especially among older adults managing multiple prescriptions.</div>  
     </div>
     <br style="clear:both;"/>
    ]]>
   </content>
   <link rel="alternate" href="https://www.dailycsr.com/Viatris-Global-Health-Initiatives-Advancing-NCD-Care-Mental-Health-and-Digital-Therapeutics_a5204.html" />
  </entry>
</feed>
